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INTRODUCTION
Type 2 diabetes is a metabolic disease whose prevalence is increas-
ing at an alarming rate.1 The accumulation of fat, particularly in 
the liver, is a key factor in the onset of insulin resistance and type 2 
 diabetes.2 Such accumulation, also known as nonalcoholic fatty liver 
disease (NAFLD), is a condition present in up to 50–75% of patients 
affected by type 2 diabetes, while it affects 20–30% of the general 
population.3 NAFLD can even progress into nonalcoholic steato-
hepatitis (NASH) which is characterized by liver inflammation and 
damage.4 Variations in dietary habits, such as increased consump-
tion of carbohydrates, together with sedentary lifestyle are in part 
responsible for the increased frequency of metabolic syndrome and 
its hepatic component, NAFLD.4,5
To date, the only treatment capable of counteracting or amelio-
rating liver steatosis is based on lifestyle intervention by means of 
caloric restriction (CR).6 However, the underlying mechanisms as 
well as the exact effects exerted by CR are largely unknown. One 
of the key genes involved in the numerous effects of CR is Sirt1, 
a homologue of the yeast silent information regulator 2 gene.7,8 
SIRT1 is a member of the Sirtuins, a family of protein deacetylases 
and ADP-ribosyltransferases involved in different pathways that 
regulate processes such as cellular metabolism, stress response, 
CR and lifespan.9,10 In mammals, seven sirtuins (SIRT1-7) have been 
identified.8 SIRT1 possesses a NAD+-dependent deacetylase activ-
ity and is capable of modulating gene expression in several key 
metabolic tissues such as liver, skeletal muscle and white adipose 
tissue (WAT) by deacetylating proteins and transcription factors. 
As shown by transgenic animal models with SIRT1 overexpres-
sion or by animals treated with SIRT1 activators, SIRT1 upregu-
lates the expression of genes that control oxidative metabolism 
and downregulates lipogenesis and inflammation, both involved 
in the development of NAFLD.11–14 Moreover, the short-term, non-
tissue specific overexpression of SIRT1 by adenoviral vectors also 
attenuated insulin resistance and hepatic steatosis.15 In contrast, 
the hepatocyte-specific deletion of Sirt1 results in hepatic steato-
sis and inflammation.16
To study the efficacy of long-term hepatocyte-specific Sirt1 gene 
transfer in preventing high carbohydrate (HC) diet-induced NAFLD 
and insulin resistance in adult mice, we took advantage of the use 
of adeno-associated viral (AAV) vectors. AAV vectors have shown 
promising results in several in vivo applications17 driving multi-year 
expression of therapeutic transgenes for a variety of diseases.18 We 
found that long-term liver-specific Sirt1 gene transfer led to upregu-
lation of key β-oxidation genes, preventing HC diet-induced triglyc-
eride accumulation, which in turn reduced macrophage infiltration 
and inflammation in the liver. Moreover, hepatic Sirt1 gene transfer 
also attenuated the insulin resistant state induced by the HC diet. 
These data suggest that AAV8-mediated hepatic SIRT1 overexpres-
sion may be a new gene therapy approach to prevent NAFLD, insu-
lin resistance and type 2 diabetes.
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Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease worldwide, and evidence suggests that it promotes 
insulin resistance and type 2 diabetes. Caloric restriction (CR) is the only available strategy for NAFLD treatment. The protein 
deacetylase Sirtuin1 (SIRT1), which is activated by CR, increases catabolic metabolism and decreases lipogenesis and inflamma-
tion, both involved in the development of NAFLD. Here we show that adeno-associated viral vectors of serotype 8 (AAV8)-mediated 
liver-specific Sirt1 gene transfer prevents the development of NAFLD induced by a high carbohydrate (HC) diet. Long-term hepatic 
SIRT1 overexpression led to upregulation of key hepatic genes involved in β-oxidation, prevented HC diet-induced lipid accumula-
tion and reduced liver inflammation. AAV8-Sirt1–treated mice showed improved insulin sensitivity, increased oxidative capacity in 
skeletal muscle and reduced white adipose tissue inflammation. Moreover, HC feeding induced leptin resistance, which was also 
attenuated in AAV8-Sirt1–treated mice. Therefore, AAV-mediated gene transfer to overexpress SIRT1 specifically in the liver may 
represent a new gene therapy strategy to counteract NAFLD and related diseases such as type 2 diabetes.
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ReSUlTS
Liver-specific Sirt1 gene transfer
The aim of our study was to assess the ability of liver SIRT1 over-
expression in preventing NAFLD induced by high carbohydrate 
consumption. We chose to use a model of NAFLD induction based 
on the feeding of animals with a diet enriched in sucrose (35% 
sucrose). The high consumption of fructose and/or sucrose for long 
periods of time has been associated with the increase in the inci-
dence of NAFLD in the western society.19 The 35% sucrose diet is 
in composition close to the human intake of sucrose and fructose 
in this  population.20 To achieve SIRT1 overexpression specifically in 
the liver, we used AAV vectors of serotype 8 and the human alpha 
1-anti-trypsin (hAAT) promoter, a well-documented combination 
that restricts transgene expression to hepatocytes.21,22 Using the 
same combination of vector serotype and promoter, a dose of 
5 × 1011 vector genomes (vg)/mice of a Gfp-coding vector adminis-
tered intravenously resulted, two weeks after vector delivery, in 55% 
specific hepatocyte transduction (Supplementary Figure S1a,b).
Mice were analyzed 15 weeks after intravenous injection of 
AAV8-hAAT-Sirt1 and AAV8-hAAT-Null vectors at a dose of 5 × 1011 
vg/mice to study the efficacy of vector transduction. The quantifica-
tion of vector genomes showed values between 5.7 and 8.0 vg/cell 
in the livers of mice that received AAV8-Sirt1 vectors. SIRT1 protein 
 overexpression was detected in the liver of AAV8-Sirt1–treated ani-
mals at levels that were 2.3-fold higher than those of Null-treated 
mice (P < 0.05) (Figure 1a). Furthermore, the observed increase in 
hepatic SIRT1 protein levels was within the range reported in situ-
ations of caloric restriction (CR),7 indicating that AAV-mediated 
Sirt1 gene transfer was mimicking physiological conditions. Then, 
we evaluated the levels of SIRT1 activity in whole liver extracts of 
treated mice with two different approaches. In agreement with 
increased SIRT1 protein expression, SIRT1 activity showed higher 
(2.5-fold increase) velocity of SIRT1-mediated deacetylation of p53, 
a known target of SIRT1,23 in AAV8-Sirt1–treated mice in compari-
son with AAV8-Null–treated animals (Figure 1b). Moreover, the lev-
els of endogenous acetylated p53 (Ac-p53Lys379) were significantly 
reduced by approximately 50% in liver nuclear extracts from mice 
that received AAV8-Sirt1 vectors (Figure 1c), corroborating the 
increase in the activity of hepatic SIRT1 after AAV8-Sirt1 injection.
Lower lipid accumulation in the liver of AAV8-Sirt1–treated mice 
fed with a HC diet
To examine whether an increase in hepatic SIRT1 expression may 
protect against the development of NAFLD, AAV8-Sirt1- and AAV8-
Null–treated mice were fed a HC diet during 15 weeks. Histological 
analysis showed that the deposition of fat in the liver was increased 
in mice fed a HC diet compared with mice fed a standard (STD) diet 
(Supplementary Figure S2a). The injection of AAV8-Null vectors did 
not affect the degree of accumulation of lipids in the liver of ani-
mals fed a HC diet (Supplementary Figure S3a). However, this lipid 
accumulation was greatly attenuated following hepatic gene trans-
fer with AAV8-Sirt1 (Figure 2a). Indeed, the triglyceride content was 
reduced by 43% in the liver of AAV8-Sirt1–treated mice in compari-
son with AAV8-Null mice (Figure 2b), in parallel with a decrease of 
17% in the weight of the organ (Figure 2c). HC diet induces lipid 
accumulation in the liver through increased lipogenesis and reduced 
β-oxidation (Supplementary Figure S2a,b).24 No differences were 
observed in the hepatic expression levels of lipogenic genes such as 
Sterol regulatory element binding transcription factor 1c (Srebf1) and 
Fatty acid synthase (Fasn) in mice that received AAV8-Sirt1 vectors 
(Data not shown). However, the liver expression of genes key to lipid 
oxidation and mitochondrial biogenesis such as Peroxisome prolif-
erative activated receptor, gamma, coactivator 1 α (Ppargc1α), Long-
chain acyl-Coenzyme A dehydrogenase (Acadl), Very long chain acyl-
CoA dehydrogenase (Acadvl), Sirtuin 6 (Sirt6) and Sirtuin 3 (Sirt3) was 
increased in treated animals (Figure 2d). A slight upregulation of 
Figure 1  Systemic administration of AAV8-hAAT-Sirt1 vectors led to specific SIRT1 overexpression in the liver. (a) A representative Western blot and its 
quantification are shown for SIRT1 in the liver, skeletal muscle (Skm), and epididymal white adipose tissue (eWAT) of mice fed with a high carbohydrate 
(HC) diet and treated with AAV8-hAAT-Null (AAV8-Null) or AAV8-hAAT-Sirt1 vectors (AAV8-Sirt1) at a dose of 5 × 1011 vg/mice for 15 weeks. (b) SIRT1 
deacetylation activity in liver crude nuclear extracts. (c) Representative western blot and quantification of Acetyl-p53-Lys379 protein levels in nuclear 
fractions from livers of AAV8-Null- and AAV8-Sirt1–treated mice, using tubulin as a loading control. All analyses were performed after 15 weeks on HC 
diet. Data represent the mean ± SEM of at least four animals per group. **P < 0.01 and ***P < 0.001 versus AAV8-Null. a.u., arbitrary units.
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Nuclear respiratory factor 1 (Nrf1) and Carnitinepalmitoyltransferase 2 
(Cpt2) mRNA was also observed in mice treated with AAV8-Sirt1 and 
fed a HC diet (Figure 2d). Furthermore, the content of PPARGC1A 
protein was also increased in the liver following AAV8-Sirt1 treat-
ment (Figure 2e). Thus, these data suggest that the reduction in 
the hepatic accumulation of lipids could result from increased 
β-oxidation in the liver of AAV8-Sirt1–treated mice.
Mice treated with AAV8-Sirt1 showed decreased macrophage 
infiltration in the liver
Immunostaining against the macrophage marker MAC-2 revealed 
a high degree of macrophage infiltration in the liver of AAV8-Null 
mice fed a HC diet, but not in that of AAV8-Sirt1–treated mice fed 
the same diet (Figure 3a). In agreement with a pro-inflammatory 
role of HC diet, AAV8-Null–treated mice fed this diet also showed 
hepatic upregulation of the macrophage marker F4/80 and the 
proinflammatory cytokines Interleukin 1β (Il1b) and Chemokine 
(C-C motif) ligand 5 (Ccl5) when compared with animals fed a STD 
diet (Supplementary Figure S4a). In contrast, HC-fed mice treated 
with AAV8-Sirt1 showed downregulation of F4/80 and Cd68 as well 
as Il1b and Ccl5 (Figure 3b). The serum levels of alanine transami-
nase (ALT) were also decreased in AAV8-Sirt1–treated mice in com-
parison with AAV8-Null–treated mice fed a HC diet (Figure 3c), but 
were not affected by the injection of the AAV8-Null vector per se 
(Supplementary Figure S3b). Altogether, these results suggest that 
SIRT1 overexpression protects the liver against HC diet-induced 
NAFLD-associated inflammation.
Serum lipid profile and glucose homeostasis
Despite having less fat accumulation in the liver, AAV8-Sirt1–treated 
mice had serum triglyceride, HDL-cholesterol, LDL-cholesterol and 
total-cholesterol levels similar to those of AAV8-Null–treated mice 
(Supplementary Figure S5a–d). However, mice receiving AAV8-Sirt1 
vectors presented a significant increase in serum free fatty acid 
levels, with no changes in glycerol levels, suggesting differences 
in free fatty acid re-esterification between AAV8-Null and AAV8-
Sirt1–treated mice (Supplementary Figure S5e,f ). The effects of 
SIRT1 overexpression on whole body glucose homeostasis were 
Figure 2 AAV8-Sirt1–treated mice showed reduced hepatic lipid accumulation when fed a high carbohydrate diet. (a) Representative sections of the 
liver from AAV8-Null– and AAV8-Sirt1–treated mice fed with a high carbohydrate (HC) diet stained with hematoxylin-eosin. Original magnification ×100. 
(b) Liver triglyceride content. (c) Liver weight (d) Expression levels of Peroxisome proliferative activated receptor, gamma, coactivator 1 α (Ppargc1α), 
Nuclear respiratory factor 1 (Nrf1), Medium-chain acyl-Coenzyme A dehydrogenase (Acadm), Long-chain acyl-Coenzyme A dehydrogenase (Acadl), Very 
long chain acyl-CoA dehydrogenase (Acadvl), Carnitinepalmitoyltransferase 2 (Cpt2), Sirtuin 6 (Sirt6), Sirtuin 3 (Sirt3), and Sirtuin 4 (Sirt4) were analyzed in 
the liver of AAV8-Null and AAV8-Sirt1 mice. (e) Representative western blot and quantification of hepatic PPARGC1a protein levels of AAV8-Null and 
AAV8-Sirt1 mice, using tubulin as a loading control. All analyses were performed after 15 weeks on HC diet. Data represent the mean ± SEM of at least 
four animals per group. *P < 0.05 and **P < 0.01 versus AAV8-Null.
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Figure 3 Lower macrophage infiltration and inflammation in the 
liver of AAV8-Sirt1–treated mice fed a high carbohydrate (HC) diet. (a) 
Immunostaining against MAC-2 (brown) in the liver of AAV8-Null and 
AAV8-Sirt1 mice. Original magnification ×100 and ×400 (insets). Red 
arrows indicate MAC-2+ cells. (b) Cd68, F4/80, Interleukin 1β (Il1b) and 
Chemokine (C-C motif) ligand 5 (Ccl5) mRNA expression levels in the liver 
of AAV8-Null and AAV8-Sirt1 mice. (c) Serum alanine transaminase (ALT) 
levels in AAV8-Null and AAV8-Sirt1 mice. All analyses were performed 
after 15 weeks on HC diet. Data represent the mean ± SEM of at least four 
animals per group. *P < 0.05 versus AAV8-Null.
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also examined. In fed conditions, no differences in glucose and 
insulin levels were observed between AAV8-Null and AAV8-Sirt1–
treated mice (Figure 4a,b). However, AAV8-Sirt1–treated mice pre-
sented decreased fasting glucose levels (Figure 4c), suggesting a 
reduction in gluconeogenesis. Nevertheless, glucose tolerance was 
similar between both groups (Figure 4d). When an intraperitoneal 
insulin tolerance test (ITT) was performed, AAV8-Sirt1–treated mice 
showed an improved response to insulin, reducing basal glucose 
levels by 60%, whereas AAV8-Null mice reduced glucose levels by 
only 40% (Figure 4e,f ).
Increased β-oxidation in skeletal muscle following AAV8-Sirt1 
treatment
AAV8-Sirt1 mice showed a trend to accumulate less triglycerides in 
skeletal muscle than AAV8-Null mice (Figure 5a), suggesting that 
β-oxidation could be upregulated in this tissue following the treat-
ment. In agreement with this hypothesis, the expression of key 
genes involved in lipid oxidation such as Mitochondrial uncoupling 
protein 2 (Ucp2), Peroxisome proliferator activated receptor δ (Ppard) 
and Pyruvate dehydrogenase kinase isoenzyme 4 (Pdk4) was increased 
in AAV8-Sirt1–treated mice (Figure 5b). In addition, the levels of 
phosphorylated AMP activated kinase (AMPK) were approximately 
50% higher in mice receiving AAV8-Sirt1 vectors versus those receiv-
ing AAV8-Null (Figure 5c). The phosphorylation of acetyl-CoA carbox-
ylase, one of the targets of AMPK, was also augmented in AAV8-Sirt1–
treated mice (Figure 5c). Thus, these results suggested that treatment 
with AAV8-Sirt1 vectors increased β-oxidation in the skeletal muscle.
Reduced hypertrophy and inflammation in eWAT of AAV8-Sirt1–
treated mice
After 15 weeks of HC diet, mice presented a greater degree of fat 
accumulation in adipose tissue, which was reflected by increased 
eWAT weight (data not shown) and mean area of adipocytes related 
to mice fed a STD diet (Supplementary Figure S6a,b). In AAV8-Sirt1–
treated mice fed a HC diet, although body weight gain and food 
intake were similar to those of AAV8-Null mice (data not shown), 
a slight decrease in eWAT weight was observed, and this was 
 associated to a 30% reduction in the mean area of adipocytes (Figure 
6a–c). Moreover, AAV8-Sirt1–treated mice presented changes in the 
distribution of white adipocyte area frequencies in eWAT, showing 
reduced number of large-sized adipocytes and increased number 
of small and intermediate-sized adipocytes (Figure 6d).
Figure 4 AAV8-Sirt1–treated mice were protected against insulin resistance induced by a high carbohydrate (HC) diet. (a) Blood glucose and (b) insulin 
levels in fed conditions are shown. (c) Fasted glucose levels. (d) Glucose tolerance was determined in fasted mice after an intraperitoneal injection of 
glucose (1 g/kg body weight), and blood glucose levels were measured at the indicated time points. On the right, area under the curve (AUC) of the 
glucose tolerance test was calculated. (e) Insulin sensitivity was determined after an intraperitoneal injection of insulin (0.75 units/kg body weight). 
Results are calculated as the percentage of initial blood glucose levels. Area under the curve (AUC) of the insulin tolerance test was calculated. All 
analyses were performed after 15 weeks on HC diet. Data represent the mean ± SEM of at least eight animals per group. *P < 0.05 versus AAV8-Null.
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WAT hypertrophy is usually linked to the development of inflam-
mation and hypoxia.25 Accordingly, HC diet induced upregulation 
of Inducible nitric oxide synthase 2 (Nos2) and Tumour necrosis factor 
α (Tnf), as well as Hypoxia inducible factor 1a (Hif1a) in eWAT when 
compared with mice fed a STD diet (Supplementary Figure S6c). In 
contrast, in AAV8-Sirt1–treated mice fed with a HC diet, the eWAT 
expression levels of Chemokine (C-C motif) Ligand 2 (Ccl2), Nos2 
and Hif1a were reduced, whereas no changes were observed in 
the anti-inflammatory cytokine Interleukin 10 (Figure 6e). In agree-
ment with the smaller size of the adipose tissue compartment in 
AAV8-Sirt1–treated mice, the eWAT expression and the serum levels 
of leptin were lower in these animals (Figure 6f ). However, no dif-
ferences in the expression or circulating levels of adiponectin were 
detected (Figure 6f ). Thus, all these data suggest that inflammation 
and hypoxia were decreased in adipose tissue following the treat-
ment with AAV8-Sirt1, although Sirt1 gene transfer was restricted 
to the liver.
AAV8-Sirt1–treated mice were more sensitive to leptin action in 
peripheral tissues
Since fructose intake triggers leptin resistance in the liver, and this 
in turn may lead to a decrease in lipid oxidation,24,26 we examined 
leptin signaling in AAV8-Sirt1–treated mice fed a HC diet. The lev-
els of hepatic mitogen-activated protein kinase Erk1/2, which is a 
target of leptin activated by phosphorylation,26 were increased in 
AAV8-Sirt1–treated mice (Figure 7a). In addition, the amount of 
the nuclear, fully activated form of Signal Transducer and Activator 
of Transcription 3 (STAT3), which is phosphorylated in response 
to leptin (STAT3-PSer727),27 was increased in the liver of mice that 
received AAV8-Sirt1 vectors (Figure 7a). The hepatic levels of STAT3-
PSer727, which are an indicator of leptin sensitivity, correlated 
negatively with serum leptin levels (Figure 7b), suggesting that 
AAV8-Sirt1–treated mice remained sensitive to leptin. In skeletal 
muscle, leptin acts mainly via AMPK activation. Thus, the observa-
tion of an increase in skeletal muscle AMPK-P/AMPK total ratio in 
AAV8-Sirt1–treated mice (Figure 5c) together with the negative cor-
relation between the AMPK-P/AMPK total ratio and serum leptin 
levels (Figure 7c), also suggested an improvement of leptin sensitiv-
ity in this tissue following treatment.
DISCUSSION
The excess of carbohydrate consumption for prolonged periods 
of time, mainly in the form of fructose or sucrose intake, is one of 
the main causes of NAFLD development.5,28 The only available 
treatment for NAFLD is based on lifestyle intervention by decreas-
ing nutrient consumption.29 One of the molecular mechanisms by 
which CR improves hepatic metabolism is SIRT1 activation.30 Thus, 
the overexpression of SIRT1 in vivo is an attractive approach to 
mimic CR. Although several studies have demonstrated that whole-
body activation of SIRT1 has beneficial effects on metabolism,11,12,14 
the tissue-specific actions of SIRT1 remain to be elucidated. Here we 
evaluated the therapeutic efficacy of the long-term overexpression 
of SIRT1 in the liver mediated by AAV8 vectors in which a hepato-
cyte-specific promoter drives transgene expression. We report for 
the first time that long-term liver-specific overexpression of SIRT1 
improves NAFLD in adult mice fed with a HC diet. Moreover, our 
study has shed light on the mechanisms by which SIRT1 activation 
counteracts the effects of HC. Liver SIRT1 overexpression increased 
lipid oxidation and reduced inflammation in the liver, improved 
insulin sensitivity, increased oxidative capacity in skeletal muscle 
and reduced white adipose tissue inflammation and counteracted 
the development of leptin resistance.
Figure 5 AAV8-Sirt1–treated mice showed increased β-oxidation capacity in skeletal muscle. (a) Triglyceride content in skeletal muscle. (b) Expression 
levels of Mitochondrial uncoupling protein 2 (Ucp2), Mitochondrial uncoupling protein 3 (Ucp3), Peroxisome proliferator activated receptor α (Pparα), 
Peroxisome proliferator activated receptor δ (Ppard), Carnitinepalmitoyltransferase 2 (Cpt2), Carnitinepalmitoyltransferase 1 (mCpt1), Peroxisome proliferative 
activated receptor, gamma, coactivator 1 α (Ppargc1α), and Pyruvate deshydrogenase kinase isoenzyme 4 (Pdk4). (c) Representative western blots and 
quantifications are shown for total AMP protein kinase (AMPKtot), phosphorylated AMPK (AMPK-P), phosphorylated Acetyl-CoA Carboxylase (ACC-P) 
and tubulin protein levels in skeletal muscle of AAV8-Null and AAV8-Sirt1 mice. Tubulin was used as a loading control. All analyses were performed after 
15 weeks on HC diet. Data represent the mean ± SEM of at least four animals per group. *P < 0.05 and **P < 0.01 versus AAV8-Null. a.u., arbitrary units.
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The levels of SIRT1 overexpression observed following AAV8-
mediated gene transfer were unexpectedly low for the dose of 
Sirt1-coding vectors used in the study. However, the quantification 
of vector genomes in the liver of these mice or the percentage of 
liver cells transduced using an equal dose of an AAV8-hAAT-Gfp vec-
tor obtained by the same manufacturing process, were within the 
range reported for AAV8-mediated gene transfer to the liver at doses 
similar to the ones used in the present study.31,32 It is worth noticing 
that similar levels of SIRT1 overexpression have been reported in 
studies in which the SIRT1 gene is delivered by systemic administra-
tion of adenoviral vectors,15 a vector type with high tropism for the 
liver, and after caloric restriction,7 suggesting the existence of regu-
latory mechanisms that control the levels of SIRT1 protein. In fact, 
mammalian SIRT1 is regulated by endogenous proteins involved in 
signal transduction and transcription, as well as by microRNAs such 
as miRNA-34a.8 Although SIRT1 overexpression was not too high, 
the measurement of SIRT1 activity and Ac-p53Lys379 levels indicated 
that the activity of SIRT1 was clearly increased in mice following 
AAV8-Sirt1 delivery.
AAV8-Sirt1–treated mice showed lower liver triglyceride content 
without changes in total body weight gain. A similar reduction in 
hepatic lipid accumulation has been observed in transgenic mice 
overexpressing SIRT1 ubiquitously or in mice treated with SIRT1 
activators.11,14 The observed upregulation of genes involved in 
β-oxidation could account for the reduced lipid accumulation in the 
liver of AAV8-Sirt1–treated mice. In particular, we documented an 
increase in the expression and protein levels of PPARGC1A, a master 
regulator of mitochondrial biogenesis and substrate utilization.33 In 
this regard, SIRT1 has been shown to upregulate PPARGC1A tran-
scription and activity by direct deacetylation of this factor.34 In con-
trast, lower Ppargc1a expression levels were reported in mice with 
hepatocyte-specific deletion of SIRT1.16 AAV8-Sirt1–treated mice 
also showed increased expression of Sirt3, a target of PPARGC1A, 
which has been reported to activate Acadl35,36 a fatty-acid oxidation 
enzyme also upregulated in the liver following the treatment with 
AAV8-Sirt1 vectors. Collectively, all these data suggest that SIRT1 
treatment increases the liver capacity to oxidate lipids, which could 
explain the reduced lipid accumulation in this tissue.
HC intake is associated with increased hepatic inflammation,29 a 
process that results from lipid peroxidation.4,37 In this situation, mac-
rophages and monocytes are important sources of pro- inflammatory 
cytokines in the liver and key players in the progression to NASH and 
its resolution.38 HC diet feeding induced vast hepatic macrophage 
infiltration in AAV8-Null mice, but this was prevented by AAV8-Sirt1 
Figure 6 Reduced adipocyte size and inflammation in epididymal white adipose tissue of AAV8-Sirt1–treated mice. (a) Epididymal white adipose 
tissue (eWAT) weight. (b) Representative sections of eWAT, stained with hematoxylin-eosin. Original magnification ×100. (c) Mean adipocyte area. (d) 
Frequency distribution of adipocyte area. (e) Leptin (Lep), Adiponectin (Adipoq), Chemokine (C-C motif) Ligand 2 (Ccl2), Inducible Nitric Oxide Synthase 2 
(Nos2), F4/80, Tumour necrosis factor α (Tnfα), Interleukin 10 (Il10), and Hypoxia Inducible Factor 1a (Hif1a) expression levels in eWAT. (f) Serum leptin and 
adiponectin levels. All analyses were performed after 15 weeks on HC diet. Data represent the mean ± SEM of at least four animals per group. *P < 0.05 
versus AAV8-Null.
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treatment as confirmed by the detection of decreased Mac-2 immu-
nostaining and the downregulation of Cd68, F4/80, Il1b, and Ccl5 
expression levels. This was in agreement with the reduction in the 
levels of proinflammatory cytokines observed in SIRT1 transgenic 
mice fed a HFD,11 while whole-body or hepatic disruption of the Sirt1 
gene resulted in increased hepatic inflammation.16,39 Moreover, Ccl5 
has been described as one of the first inflammatory markers that 
are upregulated when hepatic steatosis develops.40 Therefore, the 
observation of decreased Ccl5 expression in AAV8-Sirt1–treated mice 
further highlights that these mice are effectively protected against 
HC diet-induced NAFLD.
AAV8-Sirt1–treated mice did not only show improved liver metab-
olism, but also amelioration of insulin sensitivity. This improvement 
in glucose metabolism may result from the reduction in inflamma-
tion observed both in liver and adipose tissue, since insulin signal-
ing is well described to be impaired by inflammation.41 Moreover, 
lipid accumulation in tissues that are key to glucose disposal such as 
liver and skeletal muscle is also associated with insulin resistance.42,43 
Therefore, the lower degree of inflammation together with the 
decreased triglyceride content detected in these tissues could play 
a pivotal role in the peripheral amelioration of insulin sensitivity in 
AAV8-Sirt1–treated mice. Regarding insulin sensitivity, similar ben-
eficial effects have been reported in SIRT1 transgenic mice or mice 
treated with SIRT1 activators.12,44
Liver-specific SIRT1 overexpression was also associated with posi-
tive effects in extra-hepatic tissues, likely due to the reduced levels 
of leptin observed in serum following AAV8-Sirt1 treatment. Leptin 
is a hormone that controls whole-body metabolism and exerts its 
effects in metabolic tissues.27 HC or fructose-supplemented diets 
have been shown to provoke downregulation of lipid oxidation in 
the liver, which in turn increases leptin secretion to counteract this 
reduction in fat oxidation.24,26 Increased leptin levels are often asso-
ciated with a state of peripheral leptin resistance due to reduced 
STAT3-P-Ser727.24,26 In our study, HC diet feeding caused an increased 
in the levels of serum leptin in AAV8-Null mice and this increase was 
partially counteracted by AAV8-Sirt1 treatment, suggesting that 
AAV8-Sirt1–treated mice were not leptin resistant, as confirmed by 
the higher hepatic STAT3-P-Ser727 protein content. The preservation 
of leptin sensitivity in mice treated with AAV8-Sirt1 vectors, possibly 
due to the increased lipid oxidation in the liver, may have prevented 
the increase in leptin secretion in these mice. As a consequence, 
leptin sensitivity in skeletal muscle and adipose tissue would have 
been maintained, contributing to the higher β-oxidation in skeletal 
muscle and adipose lipolysis27 observed in AAV8-Sirt1–treated mice. 
The latter may have led to the reduction in adipocyte size and to 
the increase in serum free fatty acids levels, which may have been 
oxidized in other tissues. Thus, one of the mechanisms by which 
hepatic SIRT1 overexpression led to systemic effects could be 
through the maintenance of leptin sensitivity primarily in the liver, 
but also in other metabolic tissues.
Although overexpression of SIRT1 or its pharmacological acti-
vation reproduces the beneficial effects of caloric restriction, such 
as reduction of tissue lipid accumulation and improved insulin 
 sensitivity, SIRT1 is a deacetylase that also regulates many transcrip-
tion factors involved in numerous biological processes such as the 
regulation of cell cycle and apoptosis.8 In this regard, SIRT1 was orig-
inally considered to be a potential tumor promoter by its inhibitory 
effect on p53,23 raising the concern that overexpressing SIRT1 long-
term in humans could lead to the development of hepatic tumors. 
However, studies in transgenic animal models in which SIRT1 is 
overexpressed in the whole body or specifically in a particular tissue 
such as liver, muscle or adipose tissue have not shown any evidence 
of increased tumorigenesis.11,44–46 Indeed, new evidence suggests 
that SIRT1 activation and caloric restriction act as tumor suppressors 
in different laboratory models of ageing- and metabolic syndrome-
related cancers.23,47 Similarly, caloric restriction delays the onset of 
age-associated pathologies like diabetes and cancer in nonhuman 
primates.48 The only adverse events reported for prolonged calo-
rie restriction in humans are associated with the malnourishment 
caused by the chronic deficiency of nutrients.49 In this regard, SIRT1 
overexpression in the liver could represent an alternative to achieve 
the same beneficial effects of calorie restriction without exposing 
Figure 7 Hepatic SIRT1 overexpression counteracts the development of leptin resistance induced by a high carbohydrate diet. (a) Representative 
western blots and quantifications are shown for the active and phosphorylated form of Signal Transducer and Activator of Transcription 3 at the Serine 
727 residue (STAT3-PSer727), phosphorylated mitogen-activated protein kinase ERK1/2 (ERK1/2-P), total ERK1/2 (ERK1/2tot) and tubulin protein levels 
in liver of AAV8-Null and AAV8-Sirt1 mice. Tubulin was used as a loading control. Data represent the mean ± SEM of at least four animals per group. 
Correlation analyses between serum leptin levels and hepatic protein levels of STAT3-PSer727 (b) and serum leptin levels and the ratio AMPK-P/AMPKtot 
in skeletal muscle (c) in AAV8-Null and AAV8-Sirt1 mice. All analyses were performed after 15 weeks on HC diet. a.u., arbitrary units.
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patients to the risk of malnourishment. Further studies in longer-
lived mammals, such as dogs, are warranted to assess the long-term 
safety of the approach.
In summary, our work demonstrates that an AAV8-mediated 
gene transfer approach that allows long-term hepatic SIRT1 over-
expression counteracts HC diet-induced NAFLD and improves 
whole-body metabolism in adult mice. Given that NAFLD also pre-
dicts the predisposition to develop diabetes mellitus, hypertension 
and  dyslipidemia,4,29 the development of new approaches that can 
 potentially delay or even block the progression of NAFLD is cur-
rently a public health priority. Thus, gene therapy strategies based 
on the gene transfer of the Sirt1 gene to the liver may hold great 
potential to prevent the development of NAFLD, insulin resistance 
and type 2 diabetes.
MATeRIAlS AND MeTHODS
Animals
Three-month-old C57Bl/6 male mice were obtained from Harlan labora-
tories (Teklad, Madison, WI). Mice were kept in a specific pathogen-free 
facility (SER-CBATEG) and maintained under a light-dark cycle of 12 hours. 
Mice were fed ad libitum with a standard (STD) (2018S Harlan) or a HC diet 
(D12450B Research Diets, New Brunswick, NJ) during 15 weeks. The HC 
diet contained 70% of calories as carbohydrates and, specifically, 35% as 
sucrose, whereas the standard diet contained 60% of calories as carbohy-
drates but only 5% come from sugars. When stated, mice were fasted for 
16 hours. Animal care and experimental procedures were approved by the 
Ethics Committee in Animal and Human Experimentation of the Universitat 
Autònoma de Barcelona (UAB).
Recombinant AAV8 vectors
AAV8 vectors encoding codon-optimized murine Sirt1 or green fluorescent 
protein (Gfp) under the control of the human alpha 1-anti-trypsin (hAAT) 
promoter (AAV8-hAAT-Sirt1 and AAV8-hAAT-Gfp vectors) were generated in 
our laboratory by triple transfection of human embryonic kidney 293 cells 
and purified using an optimized cesium chloride gradient–based purifica-
tion protocol.50 A noncoding plasmid carrying the hAAT promoter was used 
to produce null particles (AAV8-hAAT-Null).
In vivo administration of AAV vectors
AAV8 vectors were administered by tail vein injection at a dose of 5 × 1011 vg/
mice in a total volume of 200 µl. One week after treatment feeding with a HC 
diet began and was maintained for four months.
Vector genome copy number
Total DNA was isolated with a MasterPureDNA Purification Kit (Epicentre 
Biotechnologies, Madison, WI) from overnight tissue digestions in protein-
ase K (0.2 mg/ml). The vector genome copy number in 20 ng of total genomic 
DNA was determined by quantitative PCR with primers and probe specific 
for the SV40 element in the AAV8-hAAT-Sirt1 vector. Forward primer: 5′- AGC 
AAT AGC ATC ACA AAT TTC ACA A -3′; reverse primer: 5′- CAG AC A TGA TAA 
GAT ACA TTG ATG AGT T -3′; probe: 5′- AGC ATT TTT TTC ACT GCA TTC TAG 
TTG TGG TTT GTC -3′. The final values were determined by comparison with 
a reference standard curve built from serial dilutions of a linearized plasmid 
bearing the hAAT- Sirt1 expression cassette used in the study supplemented 
with 20 ng/µl of irrelevant mouse genomic DNA.
Quantification of liver transduction
Three male mice were injected intravenously with 5 × 1011 vg/mice of AAV8-
hAAT-Gfp vectors and immunohistochemistry against GFP was performed 
two weeks later in the liver of these mice. Detection of GFP expression was 
performed in five random fields per section at an original magnification ×20. 
The percentage of transduced hepatocytes was calculated by dividing the 
number of GFP+ nuclei by total nuclei of each liver section.
Gene expression analysis
For quantitative real-time (RT)-PCR analysis, total RNA was extracted from dif-
ferent tissues using isolation reagent (Tripure; Roche Molecular Biochemicals, 
Mannheim, Germany) and Rneasy Mini Kit (Qiagen, Hilden, Germany). Total 
RNA (1–2 μg) was retrotranscribed using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche). RT-PCR was performed in a LightCycler 480 II (Roche) 
using LightCycler 480 SyBR Green I MasterMix (Roche). The sequences 
of the sense and antisense oligonucleotide primers used were: 36b4, 
5′TCCCACCTTGTCTCCAGTCT3′, 5′ACTGGTCTAGGACCCGAGAAG3′; Acadl, 
5′CCCATGGCATTAGCCTCTT3′, 5′AGAATAGTTCTGCTGTGTCCTGAG3′; Acadm, 
5′AGTACCCTGTGGAGAAGCTGAT3′,5′TCAATGTGCTCACGAGCTATG3′; Acadvl, 
5′GGTGGTTTGGGCCTCTCTA3′, 5′GGGTAACGCTAACACCAAGG3′; Adipoq, 5′T 
GTTCCTCTTAATCCTGCCCA3′, 5′CCAACCTGCACAAGTTCCCTT3′; Ccl2, 5′CCC 
AATGAGTAGGCTGGAGA3′, 5′TCTGGACCCATTCCTTCTTG3′; Ccl5, 5′CCTCACC 
ATCATCCTCACTGCA3′, 5′TCTTCTCTGGGTTGGCACACAC3′; Cd68, 5′GGGG 
CTCTTGGGAACTACAC3′, 5′CAAGCCCTCTTTAAGCCCCA3′; Cpt2, 5′CCAAAG 
AAGCAGCGATGG3′, 5′TAGAGCTCAGGCAGGGTGA3′; F4/80, 5′CTTTGGCTAT 
GGGCTTCCAGTC3′, 5′GCAAGGAGGACAGAGTTTATC3′; Hif1a, 5′GCACTAGA 
CAAAGTTCACCTGAGA3′, 5′CGCTATCCACATCAAAGCAA3′; Il1b, 5′TGTAATG 
AAAGACGGCACACC3′, 5′TCTTCTTTGGGTATTGCTTGG3′; Il10, 5′CTATGCTG 
CCTGCTCTTACTG3′, 5′AACCCAAGTAACCCTTAAAGTC3′; Lep, 5′GAGACCCC 
TGTGTCGGTTC3′, 5′CTGCGTGTGTGAAATGTCATTG3′; mCpt1, 5′GCACACCA 
GGCAGTAGCTTT3′, 5′CAGGAGTTGATTCCAGACAGGTA3′; Nos2, 5′CTTTGCCA 
CGGACGAGAC3′, 5’TCATTGTACTCTGAGGGCTGAC3’; Nrf1, 5’CTGCAGGT 
CCTGTGGGAATG3′, 5′ACTCGCGTCGTGTACTCATC3′; Pdk4, 5′CCTTCACCACAT 
GCTCTTCG3′, 5′CGGTTTTCTTGATGCTCGAC3′; Ppargc1a, 5′ATACCGCAAAGAG 
CACGAGAAG3′,5′CTCAAGAGCAGCGAAAGCGTCACAG3′; Ppara, 5′TCGGCGAA 
CTATTCGGCTG3′, 5′GCACTTGTGAAAACGGCAGT3′; Ppard, 5′TCCATCGTCAAC 
AAAGACGGG3′, 5′ACTTGGGCTCAATGATGTCAC3′; Sirt3, 5′TCCTCTGAAACCGG 
ATGG3′, 5′TCCCACACAGAGGGATATGG3′; Sirt4, 5′TGATGTCCAAAGGCTGG 
AA3′, 5′AGAGTTGGAGCGGCATTG3′; Sirt6, 5′GACCTGATGCTCGCTGATG3′, 
5′GGTACCCAGGGTGACAGACA3′; Tnfa, 5′CATCTTCTCAAAATTCGAGTGACAA3
′,5′TGGGAGTAGACAAGGTACAACCC3′; Ucp2, 5′ACTTTCCCTCTGGATACCGC3′, 
5′ACGGAGGCAAAGCTCATCTG3′; Ucp3, 5′CTGCACCGCCAGATGAGTTT3′, 
5′ATCATGGCTTGAAATCGGACC3′.
Western blot analysis
For total protein extracts, tissues were homogenized in protein lysis buf-
fer and centrifuged at 15,000g during 15 minutes at 4 °C. Nuclear extracts 
were isolated as previously described.24 The primary antibodies used 
were: Anti-Sirt1 (Millipore 07-131, Billerica, MA), Anti-phospho-ACC-Ser79 
(Millipore 07-303), Anti-AMPK (Cell Signalling 2532, Danvers, MA), Anti-
phospho-AMPK-Thr172 (Cell Signalling 2531), Anti-phospho-STAT3-Ser727 (Cell 
Signalling 9134), Anti-ERK1/2 (Cell Signalling 9102), Anti-phospho-ERK1/2-
Thr202/Tyr204 (Cell Signalling 9101), Anti-Acetyl-p53-Lys379 (Cell Signalling 
2570), Anti-PGC1 (Santa Cruz H-300, Dallas, TX), Anti-α-tubulin (Abcam 
ab4074, Cambridge, UK). Detection was performed using the corresponding 
horseradish peroxidase-labeled secondary antibodies and Western blotting 
detection reagent (ECL Plus; Amersham, Freiburg, Germany).
Isolation and extraction of nuclei for SIRT1 deacetylase assay
Aliquots of liver homogenate (without protease inhibitors) were spun 
through 4 ml of sucrose 30%, 10 mmol/l Tris HCl (pH 7.5), 10 mmol/l NaCl 
and 3 mmol/l MgCl2 at 1,300 g for 10 minutes at 4°C; the pellet was washed 
with cold 10 mmol/l Tris–HCl (pH 7.5) and 10 mmol/l NaCl. The nuclei were 
suspended in 200 µl of extraction buffer containing 50 mmol/l Hepes KOH 
(pH 7.5), 420 mmol/l NaCl, 0.5 mmol/l EDTA Na2, 0.1 mmol/l EGTA, and glyc-
erol 10%, sonicated for 30 seconds, and stood on ice for 30 minutes. After 
centrifugation at 20,000g for 10 minutes, the supernatant (crude nuclear 
extract) was stored at −80 °C until use.
SIRT1 deacetylase assay
SIRT1 deacetylase activity was evaluated using 50 µg of crude nuclear extract 
from livers of AAV8-Null and AAV8-Sirt1–treated mice. SIRT1 activity was 
measured using a deacetylase fluorometric assay kit (SIRT1 Activity Assay 
Kit, Abcam, ab156065). The fluorescence intensity at 440 nm (exc. 340 nm) 
was measured every 2 minutes for a total of 60 minutes immediately after 
the addition of fluorosubstrate peptide. The results are reported as relative 
fluorescence/µg of protein (AU).
Immunohistochemical and morphometrical analysis
Tissues were fixed for 24 hours in formalin, embedded in paraffin and sec-
tioned. For histological analysis, sections were deparaffinised and stained 
with haematoxylin/eosin. For immunohistochemical detection, sections 
were deparaffinised and incubated overnight at 4 °C with antibody against 
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Mac-2 (Cederlane-CL8942AP) or GFP (Abcam ab6673), washed with PBS 
three times for 5 minutes, incubated with the corresponding secondary anti-
body and revealed with ABC Complex (Vector Laboratories, UK). Sections 
were counterstained in Mayer’s haematoxylin.
Measurement of adipocyte area
The morphometric study of adipocytes’ size was performed as previously 
described.25 Four animals per group were used and at least 400 adipocytes 
per animal were analyzed.
Glucose and insulin tolerance tests
For the glucose tolerance test, awake mice, fasted overnight (16 hours) 
with free access to water, were given an intraperitoneal injection of glucose 
(1 g/kg body weight) and glucose concentration was determined in blood 
samples at indicated time points using a Glucometer Elite analyzer (Bayer, 
Leverkusen, Germany). For the insulin tolerance test, insulin (0.75 IU/kg body 
weight; Humulin regular, Eli Lilly, Indianapolis, IN) was injected intraperito-
neally into awake fed mice and glucose concentration was determined at 
indicated time points.25
Metabolite and hormone assays
The content of triglycerides in liver and quadriceps and the serum levels 
of triglycerides, total-cholesterol, HDL-cholesterol, FFAs, glycerol, insulin, 
leptin, and adiponectin were measured as previously described.25
Statistical analysis
All values are expressed as the mean ± SEM (standard error of the media). 
Differences between groups were compared by Student’s t-test. Statistical 
significance was considered if P < 0.05.
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